Connect Biopharma (Nasdaq: CNTB) announced two oral presentations scheduled for the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress in Glasgow, UK. Dr. Rekha Chaudhuri will present findings on their drug Rademikibart, focusing on its effects in treating eosinophilic-driven, Type 2 asthma. The first presentation will discuss reduction in annualized exacerbations, while the second will cover improvements in lung function. Both presentations are scheduled for June 13th, 2025, from 3:00-4:30 PM BST. The presentations will later be available on Connect's website under the presentations and publications section.
Connect Biopharma (Nasdaq: CNTB) ha annunciato due presentazioni orali previste per il Congresso Annuale 2025 dell'Accademia Europea di Allergologia e Immunologia Clinica (EAACI) che si terr脿 a Glasgow, Regno Unito. La Dott.ssa Rekha Chaudhuri presenter脿 i risultati relativi al loro farmaco Rademikibart, concentrandosi sui suoi effetti nel trattamento dell'asma di tipo 2 guidato da eosinofili. La prima presentazione tratter脿 la riduzione delle esacerbazioni annuali, mentre la seconda illustrer脿 i miglioramenti nella funzione polmonare. Entrambe le presentazioni sono programmate per il 13 giugno 2025, dalle 15:00 alle 16:30 BST. Successivamente, le presentazioni saranno disponibili sul sito web di Connect nella sezione dedicata a presentazioni e pubblicazioni.
Connect Biopharma (Nasdaq: CNTB) anunci贸 dos presentaciones orales programadas para el Congreso Anual 2025 de la Academia Europea de Alergia e Inmunolog铆a Cl铆nica (EAACI) en Glasgow, Reino Unido. La Dra. Rekha Chaudhuri presentar谩 hallazgos sobre su medicamento Rademikibart, enfoc谩ndose en sus efectos en el tratamiento del asma tipo 2 impulsado por eosin贸filos. La primera presentaci贸n abordar谩 la reducci贸n de las exacerbaciones anualizadas, mientras que la segunda cubrir谩 las mejoras en la funci贸n pulmonar. Ambas presentaciones est谩n programadas para el 13 de junio de 2025, de 3:00 a 4:30 PM BST. M谩s adelante, las presentaciones estar谩n disponibles en el sitio web de Connect, en la secci贸n de presentaciones y publicaciones.
Connect Biopharma (Nasdaq : CNTB) a annonc茅 deux pr茅sentations orales pr茅vues lors du Congr猫s annuel 2025 de l鈥橝cad茅mie europ茅enne d鈥檃llergologie et d鈥檌mmunologie clinique (EAACI) 脿 Glasgow, Royaume-Uni. La Dre Rekha Chaudhuri pr茅sentera des r茅sultats sur leur m茅dicament Rademikibart, en se concentrant sur ses effets dans le traitement de l鈥檃sthme de type 2 脿 茅osinophiles. La premi猫re pr茅sentation portera sur la r茅duction des exacerbations annuelles, tandis que la seconde abordera les am茅liorations de la fonction pulmonaire. Les deux pr茅sentations sont pr茅vues le 13 juin 2025, de 15h00 脿 16h30 BST. Elles seront ensuite disponibles sur le site web de Connect, dans la section pr茅sentations et publications.
Connect Biopharma (Nasdaq: CNTB) gab zwei m眉ndliche Pr盲sentationen bekannt, die auf dem Jahreskongress 2025 der European Academy of Allergy and Clinical Immunology (EAACI) in Glasgow, Gro脽britannien, geplant sind. Dr. Rekha Chaudhuri wird Ergebnisse zu ihrem Medikament Rademikibart vorstellen, wobei der Fokus auf dessen Wirkung bei der Behandlung von eosinophilen-getriebenem Typ-2-Asthma liegt. Die erste Pr盲sentation behandelt die Reduktion j盲hrlicher Exazerbationen, die zweite Verbesserungen der Lungenfunktion. Beide Pr盲sentationen sind f眉r den 13. Juni 2025 von 15:00 bis 16:30 Uhr BST angesetzt. Die Pr盲sentationen werden sp盲ter auf der Website von Connect im Bereich Pr盲sentationen und Ver枚ffentlichungen verf眉gbar sein.
Positive
None.
Negative
None.
SAN DIEGO, June 03, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (鈥淐onnect Biopharma鈥� or the 鈥淐ompany鈥�), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced two oral presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress, taking place聽June 13-16, 2025, in聽Glasgow, United Kingdom and virtually.
The presentation details are as follows:
Abstract Title: Reduction in Annualized Exacerbations with Rademikibart in Eosinophilic Driven, Type 2 Asthma Abstract Number: 001671 Presenter: Rekha Chaudhuri, M.D. Session Title: Clinical Trials on Airways Diseases Date and Time: Friday, June 13th from 3:00 p.m. 鈥� 4:30 p.m. BST
Abstract Title: Improvement in Lung Function with Rademikibart in Eosinophilic Driven, Type 2 Asthma Abstract Number: 001678 Presenter: Rekha Chaudhuri, M.D. Session Title: Clinical Trials on Airways Diseases Date and Time: Friday, June 13th from 3:00 p.m. 鈥� 4:30 p.m. BST
Following the presentations, each presentation will be available on Connect鈥檚 website under the .
About Connect Biopharma and Rademikibart Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the company is advancing rademikibart, a next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4R伪) antibody. With an initial focus on acute exacerbations鈥攁n area with significant unmet need鈥攔ademikibart has the potential to also drive chronic utilization in asthma and COPD amongst the approximately 1 million asthma patients and 1.3 million COPD patients in the U.S. who experience acute exacerbations annually. In a Phase 2 trial for asthma, rademikibart demonstrated strong efficacy and safety data, with clinically meaningful reductions in exacerbations and rapid, statistically significant improvements in forced expiratory volume in one second (FEV1), observed within one week鈥攁nd in most cases, within 24 hours via home spirometry.
For more information visit .
Investor Relations Contact:
Alex Lobo Precision AQ
(212) 698-8802
Media Contact:
Ignacio Guerrero-Ros, Ph.D., or David Schull Russo Partners, LLC
(858) 717-2310 or (646) 942-5604
FAQ
What will Connect Biopharma (CNTB) present at EAACI 2025?
Connect Biopharma will present two oral presentations about their drug Rademikibart, focusing on reduction in annualized exacerbations and improvement in lung function for eosinophilic-driven, Type 2 asthma.
When and where will Connect Biopharma's EAACI 2025 presentations take place?
The presentations will take place on Friday, June 13th, 2025, from 3:00-4:30 PM BST in Glasgow, United Kingdom, during the Clinical Trials on Airways Diseases session.
Who is presenting Connect Biopharma's research at EAACI 2025?
Dr. Rekha Chaudhuri will present both oral presentations on Rademikibart at the EAACI 2025 Annual Congress.
How can investors access Connect Biopharma's EAACI 2025 presentations?
The presentations will be available on Connect Biopharma's website under the presentations and publications section after the conference.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
